Table 2.
Demographics and clinical features of patients who received isavuconazole for antifungal prophylaxis
| Author | Country | Center | No. of patients | Age (years, median) | Underlying condition | Dosage of ISA: loadinga | Dosage of ISA-P: loadinga | Dosage of ISA: maintenancea | Dosage of ISA-P: maintenancea | Route | Duration | Prophylaxis outcome: IFI breakthrough |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decembrino et al., 2020 [2] | Italy/retrospective | Multi-center | 5 | 14.5 (3–18) | HM and HCT | <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h | <30 kg: 100 mg/day; >30 kg 200 mg/once daily | IV and oral | Mean 75 days | 0/5 | ||
| Kunvarjee et al., 2024 [34] | USA/retrospective | Mono-center | 20 | 14.8 (7–18) | HM and HCT | Standard | Standard | IV and oral | Not reported |
3/20 IFI: 1 proven (pathogen not available) and 2 probable/possible |
||
| Zimmerman et al., 2022 [33] | France/retrospective | Mono-center | 6 | 9 (2–11) | HM |
f <30 kg: 100 mg ×3 for 48 h If >30 kg: 200 mg ×3 for 48 h |
<30 kg: 100 mg once daily >30 kg: 200 mg once daily |
IV and oral | 90 days | 0/6 | ||
| Gatti et al., 2022 [36] | Italy/retrospective | Mono-center | 6 | 9.5 | HM | 100 mg ×3/die × 24 h | 100 mg once daily | Not reported | 174 days | 0/6 | ||
| Mendoza-Palomar et al., 2025 [35] | Spain/retrospective | Multi-center | 12 | 11 (6–14) | HM and non-hematological conditions | Not reported |
35 kg or less 5.4 mg/kg/day (max 200 mg) >35 kg 200 mg/day |
IV and oral | Median 51 days (21–101) | 0/12 |
HCT hematopoietic cell transplantation, HM hematologic malignancies, IFI invasive fungal infection, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, USA United States of America
aWe considered the standard dose for isavuconazonium was 10 mg/kg and for isavuconazole, 5.4 mg/kg administered three times a day for the first 48 h (loading dose) and then once daily (maintenance dose)